The sensitivity and specificity testes for diagnosis of rheumatoid arthritis/ Jordan
Keywords:
Rheumatoid arthritis, ANA, ACCP, ASO and CRP Laboratory TestsAbstract
Background: Prognosis, treatment, and even early detection of rheumatoid arthritis may all be effectively tracked. Serological tests may be used to validate clinically suspected preliminary diagnoses of rheumatic disorders, track the effectiveness of treatment, and predict the prognosis of autoimmune diseases. for CRP, anti-citrullinated peptide antibodies, anti-streptolysine O, acute phase proteins, rheumatoid factor, and CRP. Aims of the study: focused on diagnostic designs that tested the sensitivity and specificity of diagnoses. such as ANA, ACCP, ASO, and CRP Laboratory Tests of Rheumatoid arthritis. Methods: ELIZA tests were used to refer 79 individuals to the Immunology department, specifically the rheumatic ward. Statistical test: Statically analysis: was carried out using ANOVA. Results: Most patients with RA tested positive for anti-CCP. 86% of RA patients have positive test findings. According to ASO, there may be an increase in RF without an increase in ASO in some circumstances. This is because there may be additional health issues contributing to the auto immune disease. Other results may also indicate an increase in ASO and CRP without an increase in RF. Conclusions: We came to the conclusion that ACCP antibodies and CRP are the most sensitive and specific tests for the diagnosis of RA.
Downloads
References
Researchers at the Mayo Clinic utilize AI and biomarkers to tailor the therapy of rheumatoid arthritis Dec. 17, 2021, 4:00 p.m.
Song, G., Hu, C., Zhu, H., Wang, L., Zhang, F., Li, Y., & Wu, L. (2013). New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays. The Journal of rheumatology, 40(4), 461-468. DOI: https://doi.org/10.3899/jrheum.120264
Payet, J., Goulvestre, C., Bialé, L., Avouac, J., Wipff, J., Job-Deslandre, C., ... & Allanore, Y. (2014). Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. The Journal of rheumatology, 41(12), 2395-2402.
Rheumatoid arthritis discovery could result in new anti-inflammatories. Nov. 22, 2021, 08:31 p.m. CDT
Mayo researchers link gut microbiome to rheumatoid arthritis prognosis Sept. 14, 2021, 02:00 p.m. CDT
antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. J heumatol. 2014; 41:23952402. DOI: https://doi.org/10.3899/jrheum.131375
Published
How to Cite
Issue
Section
Copyright (c) 2024 International journal of health sciences

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.








